Dyne Therapeutics

OverviewSuggest Edit

Dyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company develops a program that will focus on using antibody-oligo conjugates to block the repetitive DNA mutations that cause the disease myotonic dystrophy type 1.

TypePrivate
Founded2018
HQWaltham, MA, US
Websitedyne-tx.com

Latest Updates

Employees (est.) (Apr 2021)56(+10%)
Job Openings15
Cybersecurity ratingBMore

Key People/Management at Dyne Therapeutics

Joshua Brumm

Joshua Brumm

President and Chief Executive Officer, Director
Catherine Stehman-Breen

Catherine Stehman-Breen

Director
Romesh Subramanian

Romesh Subramanian

Chief Scientific Officer
Oxana Beskrovnaya

Oxana Beskrovnaya

Senior Vice President, Head of Research
Mo Qatanani

Mo Qatanani

Vice President, Program & Alliance Management
Chris Mix

Chris Mix

Senior Vice President, Clinical Development
Show more

Dyne Therapeutics Office Locations

Dyne Therapeutics has an office in Waltham
Waltham, MA, US (HQ)
830 Winter St
Show all (1)

Dyne Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Dyne Therapeutics total Funding

$165 m

Dyne Therapeutics latest funding size

$115 m

Time since last funding

9 months ago

Dyne Therapeutics investors

Dyne Therapeutics's latest funding round in August 2020 was reported to be $115 m. In total, Dyne Therapeutics has raised $165 m
Show all financial metrics

Dyne Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Dyne Therapeutics Online and Social Media Presence

Embed Graph

Dyne Therapeutics News and Updates

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,0…

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive offi…

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual inve…
Show more

Dyne Therapeutics Blogs

Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases

WALTHAM, Mass., August 10, 2020 – Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital (a Citadel …

Dyne Therapeutics Appoints Susanna High as Chief Operating Officer

Veteran executive brings proven record of operational excellence in building biotech companies WALTHAM, Mass., August 3, 2020 – Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapeutics for patients with serious muscle diseases, today announced that it has appoi…

Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board

WALTHAM, Mass., July 20, 2020 – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of pediatric neurologist Francesco Muntoni, FRCPCH, FMedSci, to its Scientific Advisory Board. Dr. Muntoni is a global l…

Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property

Mr. Wilson is an experienced intellectual property attorney with deep expertise in drug development WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the appointment of Daniel Wilson as vice p…

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD

WALTHAM, Mass. –­­­ Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle he…

Dyne Therapeutics Expands Leadership Team with Key Hires

Appointments strengthen company’s capabilities across drug discovery, development and manufacturing WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the addition of three key members to its leadership…
Show more

Dyne Therapeutics Frequently Asked Questions

  • When was Dyne Therapeutics founded?

    Dyne Therapeutics was founded in 2018.

  • Who are Dyne Therapeutics key executives?

    Dyne Therapeutics's key executives are Joshua Brumm, Catherine Stehman-Breen and Romesh Subramanian.

  • How many employees does Dyne Therapeutics have?

    Dyne Therapeutics has 56 employees.

  • Who are Dyne Therapeutics competitors?

    Competitors of Dyne Therapeutics include Precigen, Ambrx and ProQR Therapeutics.

  • Where is Dyne Therapeutics headquarters?

    Dyne Therapeutics headquarters is located at 830 Winter St, Waltham.

  • Where are Dyne Therapeutics offices?

    Dyne Therapeutics has an office in Waltham.

  • How many offices does Dyne Therapeutics have?

    Dyne Therapeutics has 1 office.